Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Xu, Zhengju; Shen, Jian-kun; Pan, Xingnan; Wei, Miaoyan; Liu, Liguan; Wei, Kaipeng; Liu, Lifei; Yang, Huanwen; Huang, Jinfa

doi:10.1002/jmv.25045

Cited by 20 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels of serum GP73 rose in parallel with the severity of hepatitis and fibrosis, from nonexistent or mild to moderate and severe necroinflammation and fibrosis, even cirrhosis. These findings are similar to the recent reports demonstrating elevation of GP73 levels in HBV infection-related liver disease progression [22–24, 31, 37, 38].…”

Section: Discussionsupporting

confidence: 92%

“…Though some studies have proven that serum GP73 was a valuable candidate for diagnosing advanced fibrosis and cirrhosis [21, 23, 38, 40] and may even have a higher diagnostic value compared to the traditional noninvasive indices such as APRI, FIB-4, and liver stiffness measurement (LSM) [21, 40], some other studies prefer it to be a new effective biomarker for diagnosing liver necroinflammation [22, 24, 37]. Noticeably, all these results are mainly from patients with HBV-related liver disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

et al. 2019

View full text Add to dashboard Cite

Background and Aim. Serum Golgi protein 73 (GP73) is a promising alternative biomarker of chronic liver diseases, but most data are from patients with HBV infection rather than HCV. Materials and Methods. Two independent cohorts of chronic hepatitis C (CHC) patients from the 5th Medical Centre of the Chinese PLA General Hospital (n=174) and Beijing Youan Hospital (n=120) with different histories of HCV infection were enrolled. The correlations between serum GP73 and other biochemical indices, as well as its correlations with different stages of liver disease progression, were investigated. The receiver operating characteristic (ROC) curve was employed to evaluate the diagnostic potential of serum GP73 for liver necroinflammation and fibrosis, and comparisons of the diagnostic efficiency with traditional indices of hepatic liver injuries were further investigated. Results. Levels of serum GP73 were found significantly elevated in patients with moderate to severe inflammatory grade (G≥2) and/or with advanced fibrotic stages (F≥3) in both cohorts (P<0.05, respectively), as compared to those with a normal or mild liver lesion. Further ROC analysis demonstrated that serum GP73 was comparable to serum ALT and AST in diagnosing the liver necroinflammation grade at G≥2, but its diagnostic values for advanced fibrosis (F≥3) and cirrhosis (F=4) were limited when compared to APRI and FIB-4, and FIB-4 exhibited the best performance. Notably, an obvious elevation of serum GP73 was observed after patients received PEG-IFN and ribavirin treatment. Conclusions. Serum GP73 is an important biomarker in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection, but the value is limited for diagnosing advanced fibrosis and cirrhosis in comparison with APRI and FIB-4.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The NOS score of each study is presented in Supplementary Table 3 . Ten studies 5 , 6 , 8 , 24 , 30 , 31 , 33 , 34 , 38 were of high quality and 9 studies 7 , 25 – 29 , 32 , 35 – 37 were of moderate quality. There were no studies with low quality.…”

Section: Resultsmentioning

confidence: 99%

Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis

Zhang¹,

Li²,

Zhao³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims Chronic hepatitis B is the main cause of liver cancer. However, the most neglected group has been treatment-naive chronic hepatitis B patients with normal alanine aminotransferase (ALT). People have tended to subjectively assume that the liver lesions of these patients are not serious and do not need antiviral treatment. However, the truth is not as optimistic as we thought. We aimed in this study to analyze the proportion of significant inflammation or fibrosis in aforementioned patients. Methods Medline, Embase, and Cochrane Library were searched up to January 10 th 2020, to identify studies of these patients with liver biopsy. The double arcsine method was used with a random-effect model to combine the proportion of significant inflammation or fibrosis. Potential heterogeneity was explored by subgroup analysis and meta-regression. Outcome of interests included the proportion of significant inflammation or fibrosis and cirrhosis. The secondary outcome was to find the risk factors of significant histological changes. Results Nineteen eligible studies, with 2,771 participants, were included. The pooled proportion of significant inflammation or fibrosis was 35% [95% confidence interval (CI): 27 to 43] and 30% (95% CI: 25 to 36), respectively. The pooled proportion of cirrhosis was 3% [95% CI: 1 to 5, (12 studies; 1,755 participants)]. In subgroup analysis, old age [vs. young (<40 years-old), 44% vs. 26%, p =0.012] was significantly associated with higher fibrosis stage as well as cirrhosis [vs. young (<40 years-old), 4.8% vs. 1.8%, p <0.001]. Conclusions About 1/3 of the treatment-naive chronic hepatitis B patients with normal ALT show significant histological changes, and some even have cirrhosis.

show abstract

“…GP73 is upregulated in many chronic hepatopathies, including chronic viral hepatitis B and C, alcohol-related liver disease, and AIH [ 36 , 37 , 38 , 39 ]. Additionally, GP73 levels were considerably elevated in patients with significant necroinflammation, fibrosis, or cirrhosis [ 36 , 37 , 40 , 41 , 42 ], suggesting that GP73 could be used as a reliable surrogate marker for the detection of advanced fibrosis and cirrhosis but also for the monitoring of patients with liver diseases [ 16 , 37 , 40 , 43 , 44 , 45 ]. Indeed, recent reports have shown that serum GP73 is an accurate biomarker for the detection of significant fibrosis, bearing higher diagnostic accuracy than APRI and FIB-4 scores and that it could be used as a complementary tool to TE [ 20 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?

Gatselis

Zachou

Giannoulis

et al. 2021

Cancers

View full text Add to dashboard Cite

The cartilage oligomeric matrix protein (COMP) and Golgi-protein-73 (GP73) have been proposed as markers of liver fibrosis and hepatocellular carcinoma (HCC). Our aim was to assess the performance of the combination of these markers in diagnosing cirrhosis and predicting HCC development. Sera from 288 consecutive patients with chronic liver diseases were investigated by using COMP and GP73-ELISAs. Dual positivity for COMP (>15 U/L) and GP73 (>20 units) was observed in 24 (8.3%) patients, while 30 (10.4%) were GP73(+)/COMP(−), 37/288 (12.8%) GP73(−)/COMP(+), and 197 (68.5%) GP73(−)/COMP(−). Positivity for both markers was associated with cirrhosis [23/24 (95.8%) for GP73(+)/COMP(+) vs. 22/30 (73.3%) for GP73(+)/COMP(−) vs. 25/37 (67.6%) for GP73(−)/COMP(+) vs. 46/197 (23.4%) for GP73(−)/COMP(−); P < 0.001]. The combination of GP73, COMP, the aspartate aminotransferase/platelets ratio index, and the Fibrosis-4 score had even higher diagnostic accuracy to detect the presence of cirrhosis [AUC (95% CI): 0.916 (0.878–0.946)] or significant liver fibrosis (METAVIR ≥ F2) [AUC (95% CI): 0.832 (0.768–0.883)] than each marker alone. Kaplan-Meier analysis showed that positivity for both GP73 and COMP was associated with higher rates of HCC development (P < 0.001) and liver-related deaths (P < 0.001) during follow-up. In conclusion, the combination of GP73 and COMP seems efficient to detect cirrhosis and predict worse outcomes and the development of HCC in patients with chronic liver diseases.

show abstract

Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection

Cited by 20 publications

References 29 publications

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis

Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?

Contact Info

Product

Resources

About